Overview
- The DELFI fragmentome classifier was validated in 377 patients from Guatemala and Romania and, when combined with alpha-fetoprotein (AFP) and basic risk factors, detected hepatocellular carcinoma more often than AFP alone, including early-stage tumors.
- Researchers introduced MethID, a methylation-based method that traced circulating DNA back to hepatocytes, blood-vessel cells, and immune cells and showed those signals help the test identify liver cancer.
- The genome-wide analysis found a circulating DNA mutation pattern linked to aflatoxin exposure in Guatemalan participants, marking the first identification of that signature across the whole genome in plasma.
- The test uses less than 1 mL of plasma and low-coverage whole-genome sequencing to read fragmentation, methylation, mutations, chromatin signals, and repetitive elements, and higher fragmentome scores correlated with tumor features and survival.
- Authors and funders say the results point to a scalable, multimodal liquid-biopsy approach but stress that prospective clinical trials, cost-effectiveness studies, and implementation work are needed before routine screening or monitoring changes for patients.